7UD Stock Overview
Braster S.A. provides in-home breast cancer examination device worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Braster S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.09 |
| 52 Week High | zł942.00 |
| 52 Week Low | zł0.07 |
| Beta | 0.52 |
| 11 Month Change | 0% |
| 3 Month Change | -3.64% |
| 1 Year Change | -25.00% |
| 33 Year Change | -62.73% |
| 5 Year Change | n/a |
| Change since IPO | -67.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7UD | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -1.3% |
| 1Y | -25.0% | -8.4% | 7.4% |
Return vs Industry: 7UD underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: 7UD underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 7UD volatility | |
|---|---|
| 7UD Average Weekly Movement | 20.1% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7UD's share price has been volatile over the past 3 months.
Volatility Over Time: 7UD's weekly volatility has increased from 10% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 10 | Dariusz Karolak | www.braster.eu |
Braster S.A. provides in-home breast cancer examination device worldwide. The company offers Braster System, a device that allows every woman to perform breast examination independently at home; and Braster Pro, a certified medical device that supports the process of breast examination in clinical conditions. It also provides automatic interpretation of results of thermographic breast examination through Braster telemedical centers.
Braster S.A. Fundamentals Summary
| 7UD fundamental statistics | |
|---|---|
| Market cap | €3.96m |
| Earnings (TTM) | -€3.83m |
| Revenue (TTM) | €1.31m |
0.0x
P/S Ratio0.0x
P/E RatioIs 7UD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7UD income statement (TTM) | |
|---|---|
| Revenue | zł1.31m |
| Cost of Revenue | zł376.00k |
| Gross Profit | zł931.00k |
| Other Expenses | zł4.76m |
| Earnings | -zł3.83m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 29, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 71.23% |
| Net Profit Margin | -293.04% |
| Debt/Equity Ratio | -260.7% |
How did 7UD perform over the long term?
See historical performance and comparison